Halozyme Therapeutics
HALO
91.35
-1.69
-1.82%
Halozyme Therapeutics
US · HALO
#1276 by market cap
Listed 1970
91.35
-1.69
-1.82%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75Market Newswire · 2026/6/15
-
Rating change
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $130Market Newswire · 2026/10/13
-
Company notice
Halo Xin.com: Prompt Announcement on Disclosing the Report for the Third Quarter of 2023SZSI · 2023/10/24
-
Rating change
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115Market Newswire · 2026/10/7
-
Rating change
Analysts' Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)TipRanks · 2026/9/3
-
Rating change
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95Market Newswire · 2026/7/22
-
Company notice
Halo Technologies Holdings Ltd: HALO to issue Convertible Notes to raise up to AUD6.75mN/A · 2024/8/29
-
Rating change
Leerink Partners Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/10/8
-
Morgan Stanley Downgrades Halozyme Therapeutics(HALO.US) to Hold Rating, Raises Target Price to $109Market Newswire · 2026/11/11
-
Citizens JMP Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $149Market Newswire · 2026/11/6
-
Company notice
Better Choice Co | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-HEP Partners LLC(7.5%),HH-Halo GP LLC(7.5%), etc.SEC · 2024/2/15
-
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $109Market Newswire · 2026/11/17
-
Rating change
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $130Market Newswire · 2026/10/13
-
Company notice
Akanda | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Halo Collective Inc.(0%)SEC · 2024/2/21
-
Halozyme Therapeutics(HALO.US) Officer Sells US$6 Million in Common StockMarket Newswire · 2026/11/17
-
Company notice
RIMBACO: JOINT ANNOUNCEMENT1. CLOSE OF MANDATORY UNCONDITIONAL CASH OFFER BY CMB INTERNATIONAL CAPITAL LIMITED AND CEB INTERNATIONAL CAPITAL CORPORATION LIMITED FOR AND ON BEHALF OF AUREOLE HALO LIMITED TO ACQUIRE ALL THE ISSUED SHARES OF RIMBACO GROUP GLOBAL LIMITHKEX · 2026/7/7
-
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $130Market Newswire · 2026/11/20
-
Rating change
Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57Market Newswire · 2026/6/15
-
Rating change
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $93 to $115Market Newswire · 2026/8/8
-
Rating change
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93Market Newswire · 2026/6/15
-
Rating change
J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)TipRanks · 2026/5/20
-
GUIDANCE: (HALO) Halozyme Therapeutics Now Expects 2026 Revenue Range $1.86B - $1.93B, Vs. FactSet Est of $1.88BMT Newswires · 2026/11/6
-
GUIDANCE: (HALO) Halozyme Therapeutics Now Expects 2026 Adjusted EPS Range $8.75 - $9.05, Vs. FactSet Est of $8.62MT Newswires · 2026/11/6
-
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $130Market Newswire · 2026/11/6
-
Tesla's Roadster and the SpaceX Halo -- Barrons.comBarron's · 2026/10/19
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Halozyme Therapeutics discussion 0 comments